OBJECTIVE: Antiretroviral (ARV) drugs are routinely provided to HIV-infected pregnant women to prevent HIV mother-to-child transmission. Although ARV use has significantly reduced mother-to-child transmission to <2% in the United States, it remains crucial to monitor uninfected infants and children for adverse consequences of in utero ARV exposure. METHODS: We studied neurodevelopmental function in HIV-exposed uninfected children who were enrolled in Pediatric AIDS Clinical Trials Group 219/219C, a multisite, prospective, cohort study. Mental and motor functioning were assessed with the Bayley Scales of Infant Development (BSID), first and second editions. ARV exposure information was collected during pregnancy or within the first years of life. Linear regression methods were used to evaluate the association of in utero ARV exposure on Mental Developmental Index and Psychomotor Developmental Index at 2 years of age, controlling for demographic factors (age, gender, and race/ethnicity) and potential confounders: test version, primary language, primary caregiver, caregiver education level, low birth weight, geographic and urban/rural location, birth year, and maternal illicit drug use. RESULTS: Among 1840 infants who were born between 1993 and 2006, 1694 (92%) were exposed to ARV in utero and 146 (8%) were not exposed. After controlling for confounders, children who were exposed in utero to any ARV did not have lower Mental Developmental Index and Psychomotor Developmental Index scores than unexposed children. Among low birth weight infants, significantly higher BSID scores were observed for prenatally ARV-exposed than unexposed children. Maternal illicit drug use was reported for 17% of mothers but was not associated with BSID scores. CONCLUSIONS: Mental and motor functioning scores were not lower for infants with in utero ARV exposure compared with no exposure. Although these results are reassuring, continued evaluation of uninfected children with in utero ARV exposure for long-term adverse outcomes is important.
OBJECTIVE: Antiretroviral (ARV) drugs are routinely provided to HIV-infected pregnant women to prevent HIV mother-to-child transmission. Although ARV use has significantly reduced mother-to-child transmission to <2% in the United States, it remains crucial to monitor uninfected infants and children for adverse consequences of in utero ARV exposure. METHODS: We studied neurodevelopmental function in HIV-exposed uninfected children who were enrolled in Pediatric AIDS Clinical Trials Group 219/219C, a multisite, prospective, cohort study. Mental and motor functioning were assessed with the Bayley Scales of Infant Development (BSID), first and second editions. ARV exposure information was collected during pregnancy or within the first years of life. Linear regression methods were used to evaluate the association of in utero ARV exposure on Mental Developmental Index and Psychomotor Developmental Index at 2 years of age, controlling for demographic factors (age, gender, and race/ethnicity) and potential confounders: test version, primary language, primary caregiver, caregiver education level, low birth weight, geographic and urban/rural location, birth year, and maternal illicit drug use. RESULTS: Among 1840 infants who were born between 1993 and 2006, 1694 (92%) were exposed to ARV in utero and 146 (8%) were not exposed. After controlling for confounders, children who were exposed in utero to any ARV did not have lower Mental Developmental Index and Psychomotor Developmental Index scores than unexposed children. Among low birth weight infants, significantly higher BSID scores were observed for prenatally ARV-exposed than unexposed children. Maternal illicit drug use was reported for 17% of mothers but was not associated with BSID scores. CONCLUSIONS: Mental and motor functioning scores were not lower for infants with in utero ARV exposure compared with no exposure. Although these results are reassuring, continued evaluation of uninfected children with in utero ARV exposure for long-term adverse outcomes is important.
Authors: I C Hanson; T A Antonelli; R S Sperling; J M Oleske; E Cooper; M Culnane; M G Fowler; L A Kalish; S S Lee; G McSherry; L Mofenson; D E Shapiro Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1999-04-15
Authors: S Blanche; M Tardieu; P Rustin; A Slama; B Barret; G Firtion; N Ciraru-Vigneron; C Lacroix; C Rouzioux; L Mandelbrot; I Desguerre; A Rötig; M J Mayaux; J F Delfraissy Journal: Lancet Date: 1999-09-25 Impact factor: 79.321
Authors: K Dominguez; J Bertolli; M Fowler; V Peters; I Ortiz; S Melville; T Rakusan; T Frederick; H Hsu; P D'Almada; Y Maldonado; C Wilfert Journal: Ann N Y Acad Sci Date: 2000-11 Impact factor: 5.691
Authors: S E Lipshultz; K A Easley; E J Orav; S Kaplan; T J Starc; J T Bricker; W W Lai; D S Moodie; G Sopko; K McIntosh; S D Colan Journal: N Engl J Med Date: 2000-09-14 Impact factor: 91.245
Authors: C Chase; J Ware; J Hittelman; I Blasini; R Smith; A Llorente; E Anisfeld; C Diaz; M G Fowler; J Moye; L I Kaligh Journal: Pediatrics Date: 2000-08 Impact factor: 7.124
Authors: J P Ioannidis; E J Abrams; A Ammann; M Bulterys; J J Goedert; L Gray; B T Korber; M J Mayaux; L M Mofenson; M L Newell; D E Shapiro; J P Teglas; C M Wilfert Journal: J Infect Dis Date: 2001-01-12 Impact factor: 5.226
Authors: Kevin Robertson; Jeff Liner; James Hakim; Jean-Louis Sankalé; Igor Grant; Scott Letendre; David Clifford; Amadou Gallo Diop; Assan Jaye; Georgette Kanmogne; Alfred Njamnshi; T Dianne Langford; Tufa Gemechu Weyessa; Charles Wood; Mwanza Banda; Mina Hosseinipour; Ned Sacktor; Noeline Nakasuja; Paul Bangirana; Robert Paul; John Joska; Joseph Wong; Michael Boivin; Penny Holding; Betsy Kammerer; Annelies Van Rie; Prudence Ive; Avindra Nath; Kathy Lawler; Clement Adebamowo; Walter Royal; Jeymohan Joseph Journal: J Neurovirol Date: 2010-05 Impact factor: 2.643
Authors: Stanzi M le Roux; Kirsten A Donald; Kirsty Brittain; Tamsin K Phillips; Allison Zerbe; Kelly K Nguyen; Andrea Strandvik; Max Kroon; Elaine J Abrams; Landon Myer Journal: AIDS Date: 2018-08-24 Impact factor: 4.177
Authors: Cynthia Fair; Lori Wiener; Sima Zadeh; Jamie Albright; Claude Ann Mellins; Michael Mancilla; Vicki Tepper; Connie Trexler; Julia Purdy; Janet Osherow; Susan Lovelace; Suad Kapetanovic Journal: Matern Child Health J Date: 2013-07
Authors: Itziar Familiar; Shalean M Collins; Alla Sikorskii; Horacio Ruisenor-Escudero; Barnabas Natamba; Paul Bangirana; Elizabeth M Widen; Daniel Achidri; Harriet Achola; Daniel Onen; Michael Boivin; Sera L Young Journal: J Acquir Immune Defic Syndr Date: 2018-03-01 Impact factor: 3.731
Authors: Sumona Chaudhury; Gloria K Mayondi; Paige L Williams; Jean Leidner; Roger Shapiro; Modiegi Diseko; Gbolahan Ajibola; Penny Holding; Vicki Tepper; Joseph Makhema; Chipo Petlo; George R Seage; Shahin Lockman; Betsy Kammerer Journal: AIDS Date: 2018-06-01 Impact factor: 4.177
Authors: Megan S McHenry; Carole I McAteer; Eren Oyungu; Brenna C McDonald; Chris B Bosma; Philani B Mpofu; Andrew R Deathe; Rachel C Vreeman Journal: Pediatrics Date: 2018-02 Impact factor: 7.124
Authors: Nandita Sugandhi; Jessica Rodrigues; Maria Kim; Saeed Ahmed; Anouk Amzel; Mike Tolle; Eric J Dziuban; Scott E Kellerman; Emilia Rivadeneira Journal: AIDS Date: 2013-11 Impact factor: 4.177